Abstract
Objective: To evaluate the effect of olanzapine therapy on serum immunoglobulin levels (IgA, IgG, IgM) in male schizophrenic patients after 2 months of treatment by olanzapine at a daily dose of 20 mg. Patients and Methods: Twenty-eight patients with schizophrenia were included in this study, assessment of each case was done by a psychiatric, also included a 30 healthy subjects as a control group. Serum immunoglobulin concentrations were determined for both patients and controls by Mancini Radial Immuno-diffusion method using immunoglobulin kits. For the patients group and after 2 months therapy with olanzapine at a fixed daily dose of 20 mg, serum immunoglobulins were determined again using the same method for the assay. Results: No significant difference was found between serum levels of immunoglobulin (IgA, IgG, IgM) in schizophrenic patients before therapy in comparison to controls. Also insignificant difference was found between serum immunoglobulin levels (IgA, IgG, IgM) in schizophrenic patients after 2 months of olanzapine therapy and the controls. By comparing serum immunoglobulin levels in patients with schizophrenia before and 2 months after starting olanzapine therapy, no statistically significant difference was found. Conclusion: Olanzapine as atypical antipsychotic may not have an influence on the humoral immune response as reflected by the immunoglobulin levels (IgA, IgG, IgM)
Highlights
Received Accepted 2.9.2010 31.10.2010 ABSTRACT Objective: To evaluate the effect of olanzapine therapy on serum immunoglobulin levels (IgA, IgG, IgM) in male schizophrenic patients after 2 months of treatment by olanzapine at a daily dose of 20 mg
The aim of this study is to show the effect of atypical agents such as olanzapine on the serum immunoglobulin concentrations (IgG, IgA, IgM) in male schizophrenic patients
This study investigated the serum immunoglobulin levels (IgA, IgG, IgM) in male schizophrenic patients and the effect of olanzapine "atypical antipsychotic therapy" at a daily dose of 20 mg on their levels
Summary
Received Accepted 2.9.2010 31.10.2010 ABSTRACT Objective: To evaluate the effect of olanzapine therapy on serum immunoglobulin levels (IgA, IgG, IgM) in male schizophrenic patients after 2 months of treatment by olanzapine at a daily dose of 20 mg. Results: No significant difference was found between serum levels of immunoglobulin (IgA, IgG, IgM) in schizophrenic patients before therapy in comparison to controls. Insignificant difference was found between serum immunoglobulin levels (IgA, IgG, IgM) in schizophrenic patients after 2 months of olanzapine therapy and the controls. By comparing serum immunoglobulin levels in patients with schizophrenia before and 2 months after starting olanzapine therapy, no statistically significant difference was found. في مجموعة المرضى تم قياس ترآيز الكلوبيولينات المناعية ثانية بعد تعاطي المرضى عقار. بالمقارنة مع مجموعة الضبط .المرضى بعد شهرين من تعاطي عقار الاولانزابين بمقارنة مرضى الفصام قبل وبعد تعاطي عقار اولانزابين ان عقار الاولانزابين آعقار غير نموذجي لعلاج الفصام قد لايكون له تأثيرا على جهاز المناعة:الاستنتاج. It is a chronic condition that frequently has devastating effects on many aspects of the patient life and carries a high risk of suicide[1]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.